Effect of the calcium antagonist benidipine hydrochloride on 24-h ambulatory blood pressure in patients with mild to moderate hypertension in a double-blind study against placebo

Arzneimittel-Forschung/Drug Research

Volumn 50, Issue 7, 2000, Pages 620-625

  Nakajima, Osamu ^a   Akioka, Hisashi ^a   Miyazaki, Mizuo ^b  

^a NISSAY HOSPITAL   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Benidipine; Calcium antagonist; CAS 91559 74 5; Clinical studies, effect on ambulatory blood pressure

Indexed keywords

BENIDIPINE; CALCIUM ANTAGONIST; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; SYSTOLIC BLOOD PRESSURE;

EID: 0033925172     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300260     Document Type: Article

References (26)

1. 2+ channel blocker with a cardioprotective effect. Cardiovasc. Drug Reviews 17, 1 (1999)
2. [2] Karasawa, A., Kubo, K., Calcium antagonistic effects and the in vitro duration of action of KW-3049, a new 1,4-dihydropyridine derivative in isolated canine coronary arteries. Jpn. J. Pharmacol. 47, 35 (1988)
3. [3] Moriyama, T., Karasawa, A., Cardiovascular effects of benidipine and amlodipine in isolated tissues and anesthetized dogs. Biol. Pharm. Bull. 17, 1468 (1994)
4. [4] Karasawa, A., Kubo, K., Shuto, K. et al., Antianginal effects of the new calcium antagonist benidipine hydrochloride in anesthetized rats and spontaneously hypertensive rats. Arzneim.-Forsch./Drug res. 38 (II), 1702 (1988)
5. [5] Karasawa, A., Kubo, K., Shuto, K. et al., Pharmacological actions of benidipine hydrochloride in several isolated smooth muscles and myocardium. Arzneim.-Forsch./Drug Res. 38 (II), 1722 (1988)
6. [6] Karasawa, A., Kubo, K., Shuto, T. et al., Benefical effect of the new calcium antagonist benidipine hydrochloride on myocardial dysfunction following coronary occlusion and reperfusion in anesthetized dogs. Arzneim.-Forsch./Drug Res. 38 (II), 1717 (1988)
7. [7] Yamada, K., Usui, S., Kishida, H. et al., Clinical evaluation of benidipine hydrochloride (KW-3049) on angina pectoris. A double-blind comparative study with nifedipine. Ther. Res. 11, 1637 (1990)
8. [8] Karasawa, A., Kubo, K., Oka, T. et al., Antihypertensive effect of intravenous administration of benidipine hydrochloride and some other calcium antagonists in conscious, spontaneously hypertensive rats. Arzneim.-Forsch./Drug Res. 38 (II), 1691 (1988)
9. [9] Karasawa, A., Ikeda, J., Yamada, K. et al., Antihypertensive effects of the new calcium antagonist benidipine hydrochloride in conscious, renal hypertensive dogs. Arzneim.-Forsch./Drug Res. 38 (II), 1695 (1988)
10. [10] Nakanishi, T., Takahashi, H., Nishimura, M. et al., Effects of benidipine hydrochloride on 24-hour blood pressure. Curr. Ther. Res. 53, 270 (1993)
11. [11] Rose, M., McMahon, F. G., Some problems with antihypertensive drug studies in the context of the new guidelines. Am. J. Hypertens. 3, 151 (1990)
12. [12] Parati, G., Rizzoni, D., Omboni, S. et al., "Smoothness index" but not T/P ratio estimates balanced 24 hour blood pressure control and predicts regression of organ damage by antihypertensive treatment. J. Hypertens. 15 (suppl 4) S7, (1997)
13. [13] Pickering, T. G., Ambulatory blood pressure monitoring in clinical practice. Clin. Cardiol. 14, 557 (1991)
14. [14] Zanchetti, A., On behalf of the Italian nifedipine GITS study group. Trough: peak ratio of the blood pressure response to dihydropyridine calcium antagonists. J. Hpyertens. 12 (Suppl. 8), S 97 (1994)
15. [15] Elliott, H. L., Trough: peak ratio and twenty-four-hour blood pressure control J. Hypertens. 12 (Suppl. 5), S 29 (1994)
16. [16] Noda, H., Ito, Y., Fujita, T. et al, The antihypertensive effect and pharmacokinetics after single oral administration of benidipine hydrochloride in patients with essential hypertension. Jpn. Pharmacol. Ther. 18, S 703 (1990)
17. [17] Myers, M. G., Trough-to-peak ratio and 24-hour blood pressure control. Am. J. Hypertens. 8, 214 (1995)
18. [18] Diamant, M., Idema, R. N., Vincent, H. H., The use of fourier analysis in the calculation of trough to peak ratio from ambulatory blood pressure measurements. J. Hum. Hypertens. 12, 61 (1998)
19. [19] Omboni, S., Mancia, G., Ambulatory blood pressure monitoring in the evaluation of antihypertensive drugs. J. Hypertens. 12 (Suppl. 8), S 9 (1994)
20. [20] Raftery, E. B., Gould, B. A., The effect of placebo on indirect and direct blood pressure measurements. J. Hypertens. 8 (Suppl. 6), S 93 (1990)
21. [21] Zachariah, P. K., Sheps, S. G., Bailey, K. R. et al., Reproducibility of ambulatory blood pressure load. J. Hum. Hypertens. 4, 625 (1990)
22. [22] Chau, N. P., Chanuded, X., Mestivier, D. et al., Le placebo est-il nécessaire dans un essai clinique sur la pression artérielle ambulatuiere? Arch. Mal. Coeur. 86, 1263 1993)
23. [23] Staessen, J. A., Thijs, L., Clement, D. et al., On behalf of the Syst-Eur Investigators. Ambulatory pressure decreases on long-term placebo treatment in older patients with isolated systolic hypertension. J. Hypertens. 12, 1035 (1994)
24. [24] Zanchetti, A., Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents. J. Hypertens. 15 (Suppl. 7), S 21 (1997)
25. [25] Parati, G., Omboni, S., Rizzoni, D. et al., The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J. Hypertens. 16, 1685 (1998)
26. [26] Omboni, S., Zanchetti, A., Antihypertensive effecacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinical and ambulatory blood pressure measurements. Multicenter Study Investigators. J. Hypertens. 16, 1831 (1998)